LOS ANGELES, Oct. 16, 2023 (GLOBE NEWSWIRE) — Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We”, “Us” or “Our”) announced the successful finishing touch of its third batch. led by BCMA. CNXC-201 chimeric antigen receptor (CAR-T) mobile treatment at its U. S. production facility. U. S.
NXC-201 will be manufactured for each patient using their own T cells at our cellular immunotherapy production facility in California.
“The finishing touch of our third batch of engineering in the U. S. The U. S. represents a vital threshold for demonstrating our U. S. production capability. U. S. A. NXC-201 IND Filing in the U. S. “We are not going to be able to do anything about the U. S. ,” said Ilya Rachman, M. D. PhD, CEO of Immix Biopharma. The overall 100 percent response rate of NXC-201 in nine patients with relapsed/refractory AL amyloidosis, for whom NXC-201 earned FDA orphan drug designation, makes it a vital milestone in bringing NXC-201 to U. S. patients. . »
“Today, mobile CAR-T treatments generate more than $3 billion in annualized sales, yet because of their neurotoxicity and side effects, they are administered in only 5% of U. S. hospitals. Gabriel Morris, CFO of Immix Biopharma. NXC-201 has been administered to a giant number of patients with AL free/refractory amyloidosis and relapsed/refractory multiple myeloma. NXC-201 may be offering hope to others on waiting lists for mobile CAR-T treatments and potentially becoming the first outpatient CAR-T to expand to the remaining 95% of U. S. hospitals. U. S.
Immix Biopharma, Inc. (“ImmixBio”) (Nasdaq: IMMX) is a clinical-stage biopharmaceutical company pioneering personalized cures for oncology and immunology. Our leading CAR-T mobile healing active, NXC-201, is being developed for the treatment of relapsed/refractory AL amyloidosis and relapsed/refractory multiple myeloma. In 72 patients, 95% and 100% response rates were observed in the NEXICART-1 (NCT04720313) phase 1b/2a examination in patients with multiple myeloma and AL amyloidosis, respectively. (2023, July 17). The NXC-201 has the potential to become the world’s first ambulatory CAR-T. NXC-201 has been granted Orphan Drug Designation (ODD) by the FDA for the treatment of multiple myeloma and AL amyloidosis. Our Leadership Tissue Specific Healing Asset (TSTx), IMX-110, is in Phase 1b/2a clinical trials as a monocure and mixture clinical trial of IMMINENT-01 (NCT05840835) with BeiGene’s anti-PD-1 antibody, tislelizumab. IMX-110 has earned ODD and Pediatric Rare Disease (RPDD) Designation from the FDA. Learn more about www. immixbio. com.
About Nexcella, Inc.
Nexmobilea, Inc. , a subsidiary of Immix Biopharma, Inc. (NASDAQ: IMMX), is a clinical-stage biopharmaceutical corporation headquartered in Los Angeles, California, dedicated to the discovery and progression of novel mobile therapies for oncology and other indications. The lead candidate, BCMA-targeted next-generation CAR-T NXC-201 for relapsed/refractory multiple myeloma and relapsed/refractory AL amyloidosis, has produced 95% and 100% reaction rates in each indication, respectively, through July 17. 2023, in 72 patients. NXC-201 obtained orphan drug (ODD) designation through the FDA for the treatment of multiple myeloma and AL amyloidosis. We believe the NXC-201 has the potential to become the world’s first ambulatory CAR-T. The N-GENIUS platform allows us to discover, scale, and manufacture mobile treatments for patients who want them. To learn more about Nexmobilea, Inc. , visit www. nexmobilea. com
Forward-Looking Statements
Contacts:Mike MoyerLifeSci Advisorsmmoyer@lifesciadvisors. com
Company contact: irteam@immixbio. com